Linking diabetic cardiovascular disease with non-alcoholic fatty liver disease through L-carnitine: A hyperpolarized MRS study

Linking diabetic cardiovascular disease with non-alcoholic fatty liver disease through L-carnitine: A hyperpolarized MRS study

Detalles Bibliográficos
Main Authors:	Savic, D, Ball, V, Pavlides, M, Heather, LC, Tyler, DJ
Formato:	Conference item
Idioma:	English
Publicado:	Elsevier 2019

Títulos similares

The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD)
por: Savic, D, et al.
Publicado: (2020)

L-Carnitine stimulates in vivo carbohydrate metabolism in the Type 1 diabetic heart as demonstrated by hyperpolarized MRI
por: Savic, D, et al.
Publicado: (2021)

Simultaneous in vivo assessment of cardiac and hepatic metabolism in the diabetic rat using hyperpolarized MRS
por: Le Page, L, et al.
Publicado: (2016)

Detection and alterations of acetylcarnitine (AC) in human liver by 1H MRS at 3T after supplementation with L-carnitine
por: Savic, D, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease
por: Pavlides, M, et al.
Publicado: (2019)

Assessing the optimal preparation strategy to minimize the variability of cardiac pyruvate dehydrogenase flux measurements with hyperpolarized MRS
por: Timm, KN, et al.
Publicado: (2018)

Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
por: Na Li, et al.
Publicado: (2021-08-01)

Investigating the functional and metabolic role of carnitine in the diabetic heart using hyperpolarized MRI
por: Savic, D
Publicado: (2018)

L-Carnitine Stimulates In Vivo Carbohydrate Metabolism in the Type 1 Diabetic Heart as Demonstrated by Hyperpolarized MRI
por: Dragana Savic, et al.
Publicado: (2021-03-01)

Clinical cardiovascular applications of hyperpolarized magnetic resonance
por: Lewis, AJM, et al.
Publicado: (2020)

Fast Padé transform accelerated CSI for hyperpolarized MRS
por: Hansen, E, et al.
Publicado: (2016)

Cardiovascular Applications of Hyperpolarized MRI.
por: Tyler, D
Publicado: (2011)

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management
por: Alexandra Jichitu, et al.
Publicado: (2021-04-01)

Hyperpolarized 13 C and 31 P MRS detects differences in cardiac energetics, metabolism, and function in obesity, and responses following treatment
por: Lewis, AJM, et al.
Publicado: (2024)

Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
por: Yohwan Lim, et al.
Publicado: (2023-06-01)

The role of non-alcoholic fatty liver disease in the development of cardiovascular diseases
por: R. A Eganyan
Publicado: (2018-03-01)

In vivo carbon-13 dynamic MRS and MRSI of normal and fasted rat liver with hyperpolarized 13C-pyruvate.
por: Hu, S, et al.
Publicado: (2009)

Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease
por: Hak Soo Kim, et al.
Publicado: (2017-06-01)

Hyperpolarized magnetic resonance: a novel technique for the in vivo assessment of cardiovascular disease.
por: Schroeder, M, et al.
Publicado: (2011)

Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
por: Tae Hyun Kim, et al.
Publicado: (2021-12-01)

The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
por: Nicholas W.S. Chew, et al.
Publicado: (2022-08-01)

Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
por: Rahul Sao, et al.
Publicado: (2017-07-01)

Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting
por: Paula Luque-Linero, et al.
Publicado: (2024-05-01)

Cardiovascular Risk Induced by the Presence of Non-alcoholic Fatty Liver Disease
por: Daciana Dascalu
Publicado: (2023-04-01)

Non-alcoholic fatty liver disease and cardiovascular pathology: pathogenetic parallels
por: G. Yu. Knorring, et al.
Publicado: (2024-08-01)

Non-alcoholic fatty liver disease and cardiovascular risks: A review
por: Yulia V. Kotovskaya
Publicado: (2023-07-01)

BIOMARKERS OF CARDIOVASCULAR RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
por: Petrov I. M., et al.
Publicado: (2020-06-01)

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
por: Karthik Chandrasekharan, et al.
Publicado: (2020-01-01)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease
por: Bilon Khambu, et al.
Publicado: (2018-09-01)

Research Progress in the Correlation of Non-alcoholic Fatty Liver Disease and Metabolic-associated Fatty Liver Disease with Cardiovascular Diseases in China and Abroad
por: NI Xuetong, WANG Ruoxi, ZHANG Jing, YANG Xinghua
Publicado: (2024-06-01)

The Role of Carnitine Orotate Complex in Fatty Liver
por: Hyon-Seung Yi
Publicado: (2021-11-01)

Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy
por: A. V. Nelidova, et al.
Publicado: (2022-01-01)

Risk factors for cardiovascular disease in patients with non-alcoholic fatty liver disease with polymorbidity
por: E. V. Sevostyanova, et al.
Publicado: (2019-11-01)

Determining Subclinical Cardiovascular and Cardiac Diseases in Patients with Non-Alcoholic Fatty Liver Disease
por: Beliz Bahar Karaoğlan, et al.
Publicado: (2023-03-01)

Hyperpolarized butyrate: a metabolic probe of short chain fatty acid metabolism in the heart.
por: Ball, DR, et al.
Publicado: (2014)

Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
por: Rosa Lombardi, et al.
Publicado: (2021-02-01)

Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
por: Dongqing Wu, et al.
Publicado: (2021-07-01)

Clinical translation of hyperpolarized magnetic resonance for cardiovascular and metabolic diseases
por: Lewis, A
Publicado: (2017)

Models to predict non-alcoholic fatty liver disease linked to obesity in Morocco
por: Habiba Liba, et al.
Publicado: (2022-09-01)

NON-ALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK: SCIENTIFIC PROBLEM STATE
por: O. M. Drapkina, et al.
Publicado: (2017-11-01)